CD44 and prostate carcinoma: Almost all known transcription targets activated by the Wnt/β-catenin pathway, e.g. CTNNB1, CCCNDs, MMPs, PITX2, CD44, APCDD1, JUN [30]–[32], remain unchanged or are down-regulated in prostate cancer tissue or cell lines compared to normal tissue or cell line (Fig. S3 and Table S1).